The study was published April 12 in JAMA Cardiology.
Trans fatty acids, or trans fats, are commonly found in foods such as chips, crackers, fried foods, and baked goods. Minimal amounts of trans fat intake are linked to greater risk of cardiovascular disease, the leading cause of death worldwide. In recent years, localities like New York City enacted policies to reduce trans fats in restaurants and other eateries. In 2018, an FDA ban on partially hydrogenated oil in foods, which will nearly eliminate dietary trans fat, takes effect nationwide.
To study the impact of restricting trans fats, Dr. Eric Brandt and his
They found that three or more years after the restrictions were implemented, people living in areas with restrictions had significantly fewer hospitalizations for heart attack and stroke based on trends in similarly urban areas without the restrictions. The decline for the combined conditions was 6.2%.
«It is a pretty substantial decline," said Brandt, a clinical fellow in cardiovascular medicine at Yale School of Medicine. «Our study highlights the power of public policy to impact the cardiovascular health of a population. Trans fats are deleterious for cardiovascular health, and minimizing or eliminating them from the diet can substantially reduce rates of heart attack and stroke.»
The study results point to the possibility of much more widespread benefit as the FDA’s measure — which restricts trans fats in all food — are due to take effect in 2018, said Brandt.
«Even though some companies have reduced the amount of trans fat in food, current FDA labeling guidelines allow up to 0.49 grams of trans fat per serving to be labeled as 0 grams, leaving consumers to scour labels for hidden trans fats, usually labeled as partially hydrogenated oils. With the upcoming FDA regulation, people need not be so vigilant. A nationwide trans fat ban is a win for the millions of people at risk for cardiovascular disease," he said.
Other study authors are Rebecca Myerson, Marcelo Coca Perraillon, and Tamar S. Polonsky.
This research was supported by the American Medical Association Seed Grant Research Program and the National Center for Advancing Translational Sciences of the National Institutes of Health.